Market Trading Guide: NMDC Among Two Stock Recommendations for Tuesday

Why It Matters

The recommendations highlight potential upside in two high‑growth Indian stocks while the broader market remains weak, offering investors a technical‑driven entry point.

Key Takeaways

• NMDC target $1.26, stop $1.05, bullish higher‑highs pattern.
• Laurus Labs target $19.0, stop $15.8, breakout above long‑term resistance.
• Both stocks trade above key moving averages, indicating strong trend.
• RSI above neutral for NMDC, bullish for Laurus, showing momentum.
• Recommendations come as Indian indices log fourth consecutive loss.

Pulse Analysis

India’s equity markets have been under pressure, logging a fourth straight session of losses amid foreign‑institutional outflows and geopolitical uncertainty. In this environment, technical analysis often becomes a decisive factor for traders seeking short‑term opportunities. The recent ETMarkets note spotlights two stocks—NMDC and Laurus Labs—that have broken through key resistance levels, offering a contrarian edge for investors willing to follow chart‑driven signals rather than macro sentiment alone.

NMDC, a state‑controlled miner, is trading around Rs 93 (~$1.12) and has formed a classic higher‑highs, higher‑lows pattern on the daily chart. The stock sits comfortably above its 20‑day and 50‑day moving averages, and a surge in volume confirms the breakout from a prior consolidation zone. With the Relative Strength Index holding above the neutral 50 mark, momentum remains intact without signs of overextension. The target of Rs 105 (~$1.26) reflects a roughly 13% upside, positioning NMDC as a potential beneficiary of any rebound in commodity demand or policy‑driven infrastructure spending.

Laurus Labs, a pharmaceutical manufacturer, is priced near Rs 1,388 (~$16.73) and has recently eclipsed a long‑term resistance barrier, trading close to its all‑time high. The stock’s bullish trajectory is reinforced by sustained buying volume and an RSI firmly in the bullish zone, indicating robust investor confidence. With a target of Rs 1,580 (~$19.04), the upside potential exceeds 13%, aligning with expectations of continued growth in the Indian pharma sector driven by generic drug launches and export opportunities. Together, these technical setups provide a compelling narrative for risk‑aware traders looking to capitalize on sector‑specific strength amid a broader market downturn.